Zacks Rating on Mast Therapeutics (MSTX)

Mast Therapeutics (MSTX) : The consensus on Mast Therapeutics (MSTX) based on 4 analyst recommendation on the company stock is 1, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels.

Mast Therapeutics (MSTX) : Average target price received by Mast Therapeutics (MSTX) is $2.67 with an expected standard deviation of $2.08. The most aggressive target on the stock is $5, whereas the most downbeat target is $1. 3 financial analysts are currently covering the stock.


Mast Therapeutics, Inc. has lost 1.19% in the last five trading days and dropped 1.19% in the last 4 weeks. Mast Therapeutics, Inc. is up 33.87% in the last 3-month period. Year-to-Date the stock performance stands at -1.19%. Mast Therapeutics (NYSEMKT:MSTX): stock turned positive on Tuesday. Though the stock opened at $0.4003, the bulls momentum made the stock top out at $0.42 level for the day. The stock recorded a low of $0.4001 and closed the trading day at $0.415, in the green by 0.27%. The total traded volume for the day was 1,399,640. The stock had closed at $0.4139 in the previous days trading.

Mast Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops therapies for serious or life-threatening diseases with unmet needs. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, the Companys lead product candidate. Vepoloxamer is being tested in a Phase III clinical study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. AIR001 is being tested in multiple institution-sponsored Phase IIa clinical studies that provide the Company with data on AIR001s potential to treat patients with preserved ejection fraction (HFpEF).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.